The Journal of Immunology, Vol 146, Issue 4 1155-1162, Copyright © 1991 by American Association of Immunologists

ARTICLES

Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1

S Jacobson, JS Reuben, RD Streilein and TJ Palker
Neuroimmunology Branch, National Institutes of Health, National Institute of Neurologic Disease and Stroke, Bethesda, MD 20892.

Although the humoral response to human T lymphotropic virus type-1 (HTLV-I) has been well characterized in patients with HTLV-I-associated neurologic disease (HAM/TSP), little is known about a functional HTLV-I- specific human T cell response, such as CTL, in these patients. To define both the phenotype of the responding CTL and the fine specificity of this response, long term T cell lines were generated from two HAM/TSP patients who were from two different countries. Patient's peripheral blood lymphocytes were repeatedly stimulated in vitro with an HTLV-I expressing autologous T cell line. The resultant long term T cell culture was shown to be CD4+ and cytotoxic for targets expressing HTLV-I Ag. Using a panel of synthetic peptides that span hydrophilic regions of the HTLV-I gp46 envelope glycoprotein, the CTL lines generated from both patients were shown to recognize the same region of the HTLV-I envelope between amino acids 196-209 as defined by the synthetic peptide sp4a1. Interestingly, this sequence overlaps a region of HTLV-I envelope that had also been shown to elicit a strong B cell response in HAM/TSP patients (amino acids 190-203). One CTL line recognized this HTLV-I epitope in the context of HLA DQ5 whereas the other CTL line was restricted by HLA DRw16. The generation of two independent CTL lines from two HAM/TSP patients from different geographic areas that recognize the same region of the HTLV-I envelope glycoprotein highlights the immunogenic nature of this envelope region.

This article has been cited by other articles:

				H. Kobayashi, T. Nagato, M. Yanai, K. Oikawa, K. Sato, S. Kimura, M. Tateno, R. Omiya, and E. Celis Recognition of Adult T-Cell Leukemia/Lymphoma Cells by CD4+ Helper T Lymphocytes Specific for Human T-Cell Leukemia Virus Type I Envelope Protein Clin. Cancer Res., October 15, 2004; 10(20): 7053 - 7062. [Abstract] [Full Text] [PDF]

				S. Hanabuchi, T. Ohashi, Y. Koya, H. Kato, A. Hasegawa, F. Takemura, T. Masuda, and M. Kannagi Regression of Human T-cell Leukemia Virus Type I (HTLV-I)-Associated Lymphomas in a Rat Model: Peptide-Induced T-Cell Immunity J Natl Cancer Inst, December 5, 2001; 93(23): 1775 - 1783. [Abstract] [Full Text] [PDF]

				P. Hollsberg Mechanisms of T-Cell Activation by Human T-Cell Lymphotropic Virus Type I Microbiol. Mol. Biol. Rev., June 1, 1999; 63(2): 308 - 333. [Abstract] [Full Text] [PDF]

				P. Hollsberg and D. A. Hafler Pathogenesis of Diseases Induced by Human Lymphotropic Virus Type I Infection N. Engl. J. Med., April 22, 1993; 328(16): 1173 - 1182. [Full Text]